NAVIDEA BIOPHARMACEUTICALS, INC. — Revenue by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/4f193d9d-6afe-4fd8-a9ff-78560d0cb823/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2023 | $6.5k | 2022-01-01 – 2023-06-30 | evidence 0001437749-23-023319 |
| FY 2022 | $14.6k | 2022-01-01 – 2022-12-31 | evidence 0001437749-23-008054 |
| FY 2021 | $531.5k | 2021-01-01 – 2021-12-31 | evidence 0001437749-22-007390 |
| FY 2020 | $915.0k | 2020-01-01 – 2020-12-31 | evidence 0001437749-21-007329 |
| FY 2019 | $657.8k | 2019-01-01 – 2019-12-31 | evidence 0001437749-20-005567 |
| FY 2018 | $338.0k | 2018-01-01 – 2018-12-31 | evidence 0001437749-19-005086 |
| FY 2017 | $1.8M | 2017-01-01 – 2017-12-31 | evidence 0001437749-18-004756 |
| FY 2016 | $5.0M | 2016-01-01 – 2016-12-31 | evidence 0001437749-17-020777 |
| FY 2015 | $3.0M | 2015-01-01 – 2015-12-31 | evidence 0001437749-17-020777 |
| FY 2014 | $2.1M | 2014-01-01 – 2014-12-31 | evidence 0001437749-17-020777 |
| FY 2013 | $614.4k | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-015173 |
| FY 2012 | $0 | 2012-01-01 – 2012-12-31 | evidence 0001445305-14-001051 |
| FY 2011 | $0 | 2011-01-01 – 2011-12-31 | evidence 0001445305-14-001051 |
| FY 2010 | $617.4k | 2010-01-01 – 2010-12-31 | evidence 0001144204-13-016705 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
NAVIDEA BIOPHARMACEUTICALS, INC. — all facts · Net Income · Operating Income